Creative Biolabs develops antibodies for researchers who need to distinguish the Thomsen-Friedenreich T antigen from its sialylated sT form, or deliberately recognize both within a defined study.
The two epitopes differ by a terminal sialic acid, but their accessibility also depends on the carrier protein, glycosylation site, density, and surrounding glycocalyx. We design the project around the binding profile your adhesion or glycosylation research actually requires.
We offer Anti-TACA Antibody Development Service that includes a dedicated custom anti-T/sT antibody service to address this challenge. We design and develop high-affinity, high-specificity antibodies that recognize only the T antigen or only the sT antigen. These precision tools—your custom T antibody or sT antibody—are essential for accurately studying cancer cell adhesion.
T and sT are closely connected products of mucin-type O-glycosylation, and a strong response to one synthetic antigen does not guarantee clean discrimination on cells. Low immunogenicity, peptide-context recognition, and cross-reactivity with Tn or sTn can all complicate clone selection. The project must therefore define whether sialylation should abolish binding, create binding, or remain compatible with it.
| Desired profile | Key comparison |
|---|---|
| T selective | Reject sT, Tn, sTn, and unmodified peptide |
| sT selective | Match sialic-acid linkage and reject unsialylated T |
| T/sT cross-reactive | Demonstrate intended breadth without extending to Tn/sTn |
| Backbone restricted | Compare the same glycans on alternate peptide sequences |
Reciprocal T/sT selection treats core-1 glycopeptide identity and sialic-acid linkage as separate experimental variables. T-versus-sT selectivity cannot be inferred from target-only glycopeptide binding when Tn and sTn exclusions is absent from the comparison panel. The core-1 comparison plan should also record peptide-backbone dependence, because an apparently strong clone may be recognizing presentation context rather than the intended carbohydrate surface. That sialylation-dependent distinction determines which specificity tracks remain interpretable after the assay format changes.
Our dedicated T/sT service page combines custom antigen design with hybridoma or phage-display discovery, positive/negative glycopeptide screening, and validation in the requested assay context. Creative Biolabs can support monoclonal or recombinant research formats and optional labeling, while the screening strategy is customized to separate T, sT, Tn, sTn, and unmodified peptide recognition as needed.
Immunogen planning considers the exact core-1 structure, sialic-acid linkage, Ser/Thr attachment site, peptide backbone, linker, carrier, and antigen density. These variables are documented before candidate generation so the intended binding profile remains testable.
Candidate evaluation separates target binding from peptide-only, carrier-driven, or density-dependent recognition. Focused glycan panels are complemented by glycoprotein, cell, or tissue models when those contexts are part of the intended application.
During antigen planning, O-glycan density has to be varied deliberately instead of left as an uncontrolled property of the reagent. Parallel constructs help reveal whether reciprocal counter-selection changes specificity track ranking, while glycoengineered cells identifies signal unrelated to the nominated epitope. These comparisons are especially useful before investing in downstream formatting, because reformatting cannot rescue a binder whose original specificity was defined by an incidental scaffold feature.
Defined glycopeptides preserve the O-glycan–peptide junction; carrier conjugates provide immunogenic display; glycoproteins and cells supply native density. Using one format for every stage can select presentation-specific binders, so immunogen and screening reagents should be related but not identical.
The screening cascade is most informative when array-to-cell translation is assessed alongside antibody valency. One readout describes structural preference; the other tests whether the preference survives the valency, accessibility, and competing surfaces present in the intended model. Candidates that change rank between these settings are not automatically unsuitable, but the difference must be explained before a lead is selected for an application-specific study.
A focused array can resolve truncation and sialylation patterns; engineered cells can test whether binding follows core-1 synthase or sialyltransferase status. Both are needed because glycan density and membrane organization may change the apparent selectivity observed on purified antigens.
Data interpretation distinguishes a measured glycopeptide binding profile from a universal property of the antibody. Evidence for cross-reactive profile is limited to the structures, concentrations, and presentation formats actually tested. Changes in density, matrix, or antibody format can alter apparent selectivity through avidity. Reporting these boundaries makes it easier to decide whether additional controls, a second assay geometry, or a different specificity track is needed.
We first agree on the intended profile: T-selective, sT-selective, or defined cross-recognition. Matched glycopeptides and controls are then incorporated into antigen preparation and screening, allowing unwanted clones to be removed early. Selected candidates are compared across the truncated O-glycan panel and confirmed in the customer's intended cellular, tissue, or biochemical assay before handoff.
Remove peptide-only binders with the unglycosylated backbone.
Apply reciprocal T/sT negatives and Tn/sTn controls.
Use an alternate carrier or solution competition before cell-based triage.
Workflow decisions are staged so that inexpensive structural questions precede more complex biological confirmation. adhesion-model controls can narrow the specificity track set, whereas tissue fixation tests a different source of apparent selectivity. Across the reciprocal screens, positive and negative controls are interpreted together. A high target signal without a matched counter-target response does not establish specificity, and a negative result may reflect inaccessible antigen rather than absence of recognition.
The agreed scope may include selected antibody candidates, target and counter-target screening results, and application-context validation data. The final package is defined around the requested recognition profile rather than an assumed universal T/sT reagent.
Project inputs should describe carrier and linker glycopeptide binding in enough detail to reproduce the intended antigen context and should identify how solution competition will be evaluated. This information affects reagent choice, control construction, and the meaning of a negative result. If a customer sample is the final destination, its preparation history and expected target abundance are considered during planning rather than introduced only after purified-antigen screening is complete.
Compare T, sT, Tn, and sTn presentation in glycoengineered models.
Map truncated O-glycans in cells and tissues.
Investigate galectin- or selectin-associated adhesion hypotheses.
Develop structure-defined reagents for array, flow, imaging, or competition assays.
For research applications, functional interpretation is evaluated as a separate question from antigen recognition. Binding may justify advancing a specificity track, but it does not by itself demonstrate blocking, internalization, signaling, staining, or biological activity. Those endpoints require their own controls and model-specific acceptance logic. Maintaining this separation prevents a descriptive glycopeptide binding reagent from being overinterpreted as a functional antibody.
Berois, Pittini, and Osinaga describe the Tn, Thomsen-Friedenreich (TF/T), and sialyl-Tn antigens as simple mucin-type O-glycan tumor-associated carbohydrate antigens. In mucin-type O-glycosylation, GalNAc is first attached to Ser/Thr to form Tn; core 1 β3-galactosyltransferase (C1GalT1) can then add galactose to generate the core 1 disaccharide Galβ1-3GalNAcα-O-Ser/Thr, the TF/T antigen. The review explains that aberrant glycosylation in cancer produces truncated or otherwise altered glycan structures and can affect processes including cell-cell adhesion, cell-matrix interaction, proliferation, invasion, and metastasis. It also notes that the immunological definition of a glycan epitope can be more complex than its chemical structure because some antibodies recognize carbohydrate together with peptide context. Together, these observations show that O-glycan structure and peptide context can both influence the definition of antibody-recognized epitopes.
Please share whether T, sT, or both are intended targets; the relevant peptide or protein context; glycosylation sites; structures that must be excluded; available sample models; final assay; and preferred antibody format. Creative Biolabs will use these parameters to discuss an antigen, screening, and validation plan aligned with your research question.
